Clinical Trial Update: Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Gemcitabine and Nab-Paclitaxel with vs without Durvalumab and Tremelimumab as first-line therapy for metastatic pancreatic adenocarcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Canadian Cancer Trials Group | Conditions: Pancreatic Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-05-28